Market Overview:
The global joint disease therapeutics market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of joint diseases, increasing awareness about available treatment options, and technological advancements in the field of joint disease therapeutics. The drug therapy segment is expected to dominate the global joint disease therapeutics market during the forecast period. This can be attributed to the high adoption rate of drugs for treating various types of joint diseases and growing demand for novel therapies for treating chronic conditions such as arthritis. The rehabilitation segment is projected to grow at a higher CAGR than other segments during the forecast period owing to its ability to improve quality of life in patients with chronic joint diseases.
Product Definition:
Joint disease therapeutics is the study and treatment of joint diseases. Joint diseases are a group of conditions that affect the joints, the tissues that surround them, and/or the ligaments that hold them together. Joint disease therapeutics is important because it helps to improve the quality of life for people who suffer from joint diseases.
Drug Therapy:
Drug therapy is the use of drugs to treat a disease. The major factor that propels the growth of this market includes increasing incidences of diseases such as osteoarthritis, rheumatoid arthritis and other joint-related disorders. According to data published by Arthritis Foundation in 2017, around 78 million people in U.S are anticipated to be diagnosed with arthritis by 2040; making it one of the most common chronic diseases in U.S.
Rehabilitation:
Rehabilitation is an active process of restoring body functions to normal. It helps in the prevention and treatment of disabilities caused due to disease or injury. The term rehabilitation has been derived from two Latin words, namely, re - "again" andibo - "to lead" (re-lead). Hence it means leading a healthy life again.
Application Insights:
The others segment held the largest share of the global market in 2017. This is due to an increase in demand for minimally invasive procedures and adoption of advanced technologies such as 3D imaging, robot-assisted surgeries, and biologics. Minimally invasive surgeries are gaining popularity due to their associated benefits such as less pain & trauma, faster healing process, lesser blood loss & reduced risk of infection compared to conventional open surgical techniques. The hospital segment is expected to be fastest growing application over the forecast period owing to increasing investments by governments in healthcare infrastructure development along with technological advancements that have led to cost reduction when it comes down medical procedures. For instance, introduction of telehealth services has enabled patients suffering from joint diseases or orthopedic conditions requiring surgery a better opportunity for consultation and preoperative planning at a distance while minimizing travel time and costs involved which will drive growth further over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario, and high disease prevalence are some of the major factors contributing to its growth. In addition, increasing government initiatives for tackling joint-related disorders is expected to drive this regional market over the forecast period. For instance, in 2014 Medicare announced that it will cover 80% cost for patients undergoing total hip or knee replacement surgery through a coverage gap payment scheme known as Open Payments program.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising healthcare expenditure by governments and private sectors coupled with growing awareness about various treatment options available for joint diseases such as osteoarthritis and rheumatoid arthritis among others. Moreover, improving healthcare infrastructure along with an increase in disposable income is also likely to contribute toward its rapid growth over next eight years (2018 - 2030).
Growth Factors:
- Increasing incidence of joint diseases: The global incidence of joint diseases is increasing at a rapid pace. This is primarily attributed to the changing lifestyle and dietary habits of people across the world. Joint diseases are now becoming more common among all age groups, thereby driving the demand for joint disease therapeutics.
- Growing awareness about joint disease treatments: There is a growing awareness among people about various types of joint diseases and their treatments options available in the market. This is helping to drive the demand for Joint Disease Therapeutics market globally.
- Rising R&D expenditure by key players: Key players in Joint Disease Therapeutics market are investing heavily in R&D activities to develop novel therapies for treating various types of joint diseases. This is helping to fuel the growth of this market globally.
Scope Of The Report
Report Attributes
Report Details
Report Title
Joint Disease Therapeutics Market Research Report
By Type
Drug Therapy, Rehabilitation, Surgical Operation
By Application
Hospital, Clinic, Others
By Companies
AbbVie, Pfizer, Bristol-Myers Squibb, Roche, GlaxoSmithKline, AstraZeneca, Astellas Pharma, Johnson&Johnson, Amgen, Novartis, Sanofi, Daiiachi Sankyo
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
179
Number of Tables & Figures
126
Customization Available
Yes, the report can be customized as per your need.
Global Joint Disease Therapeutics Market Report Segments:
The global Joint Disease Therapeutics market is segmented on the basis of:
Types
Drug Therapy, Rehabilitation, Surgical Operation
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Pfizer
- Bristol-Myers Squibb
- Roche
- GlaxoSmithKline
- AstraZeneca
- Astellas Pharma
- Johnson&Johnson
- Amgen
- Novartis
- Sanofi
- Daiiachi Sankyo
Highlights of The Joint Disease Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Drug Therapy
- Rehabilitation
- Surgical Operation
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Joint Disease Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Joint Disease Therapeutics (JDT) is a biotechnology company focused on the development of novel therapeutics for joint diseases. The company's lead product candidate, JDT-301, is an investigational drug designed to improve the treatment of rheumatoid arthritis (RA).
Some of the key players operating in the joint disease therapeutics market are AbbVie, Pfizer, Bristol-Myers Squibb, Roche, GlaxoSmithKline, AstraZeneca, Astellas Pharma, Johnson&Johnson, Amgen, Novartis, Sanofi, Daiiachi Sankyo.
The joint disease therapeutics market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Joint Disease Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Joint Disease Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Joint Disease Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Joint Disease Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Joint Disease Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Joint Disease Therapeutics Market Size and Y-o-Y Growth
4.5.2 Joint Disease Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Joint Disease Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Joint Disease Therapeutics Market Size Forecast by Type
5.2.1 Drug Therapy
5.2.2 Rehabilitation
5.2.3 Surgical Operation
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Joint Disease Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Joint Disease Therapeutics Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Joint Disease Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Joint Disease Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Joint Disease Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Joint Disease Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Joint Disease Therapeutics Market Size Forecast by Type
9.6.1 Drug Therapy
9.6.2 Rehabilitation
9.6.3 Surgical Operation
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Joint Disease Therapeutics Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Joint Disease Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Joint Disease Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Joint Disease Therapeutics Market Size Forecast by Type
10.6.1 Drug Therapy
10.6.2 Rehabilitation
10.6.3 Surgical Operation
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Joint Disease Therapeutics Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Joint Disease Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Joint Disease Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Joint Disease Therapeutics Market Size Forecast by Type
11.6.1 Drug Therapy
11.6.2 Rehabilitation
11.6.3 Surgical Operation
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Joint Disease Therapeutics Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Joint Disease Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Joint Disease Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Joint Disease Therapeutics Market Size Forecast by Type
12.6.1 Drug Therapy
12.6.2 Rehabilitation
12.6.3 Surgical Operation
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Joint Disease Therapeutics Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Joint Disease Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Joint Disease Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Joint Disease Therapeutics Market Size Forecast by Type
13.6.1 Drug Therapy
13.6.2 Rehabilitation
13.6.3 Surgical Operation
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Joint Disease Therapeutics Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Joint Disease Therapeutics Market: Competitive Dashboard
14.2 Global Joint Disease Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie
14.3.2 Pfizer
14.3.3 Bristol-Myers Squibb
14.3.4 Roche
14.3.5 GlaxoSmithKline
14.3.6 AstraZeneca
14.3.7 Astellas Pharma
14.3.8 Johnson&Johnson
14.3.9 Amgen
14.3.10 Novartis
14.3.11 Sanofi
14.3.12 Daiiachi Sankyo
